Microbial nucleic acids pay a Toll in kidney disease

American Journal of Physiology - Renal Physiology

Volumn 291, Issue 3, 2006, Pages

  Pawar, Rahul D ^a   Patole, Prashant S ^a   Wörnle, Markus ^a   Anders, Hans Joachim ^a,b  

^a UNIVERSITY OF MUNICH   (Germany)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Glomerulonephritis; Lupus nephritis; Toll like receptors

Indexed keywords

DOUBLE STRANDED RNA; NUCLEIC ACID; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9;

AMINO ACID SEQUENCE; CELL TYPE; CELLULAR DISTRIBUTION; EUKARYOTE; GENETIC CODE; GLOMERULONEPHRITIS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; KIDNEY BLOOD VESSEL; KIDNEY DISEASE; KIDNEY GRAFT REJECTION; LUPUS ERYTHEMATOSUS NEPHRITIS; MICROORGANISM; MORPHOLOGY; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; SIGNAL TRANSDUCTION; VASCULITIS;

EID: 33748420814     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00453.2005     Document Type: Review

References (83)

1. Akira S, Uematsu S, and Takeuchi O. Pathogen recognition and innate immunity. Cell 124: 783-801, 2006.
2. Alexopoulou L, Holt AC, Medzhitov R, and Flavell RA. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature 413: 732-738, 2001.
3. Anders HJ, Banas B, Linde Y, Weller L, Cohen CD, Kretzler M, Martin S, Vielhauer V, Schlöndorff D, and Gröne HJ. Bacterial CpG-DNA aggravates immune complex glomerulonephritis: role of TLR9-mediated expression of chemokines and chemokine receptors. J Am Soc Nephrol 14: 317-326, 2003.
4. Anders HJ, Banas B, and Schlöndorff D. Signaling danger: toll-like receptors and their potential roles in kidney disease. J Am Soc Nephrol 15: 854-867, 2004.
5. Anders HJ, Vielhauer V, Eis V, Linde Y, Kretzler M, Perez de Lema G, Strutz F, Bauer S, Rutz M, Wagner H, Gröne HJ, and Schlöndorff D. Activation of toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice. FASEB J 18: 534-536, 2004.
6. Applequist SE, Wallin RP, and Ljunggren HG. Variable expression of Toll-like receptor in murine innate and adaptive immune cell lines. Int Immunol 14: 1065-1074, 2002.
7. Ashman RF, Goeken JA, Drahos J, and Lenert P. Sequence requirements for oligodeoxyribonucleotide inhibitory activity. Int Immunol 17: 411-420, 2005.
8. Barton GM, Kagan JC, and Medzhitov R. Intracellular localization of Toll-like receptor 9 prevents recognition of self DNA but facilitates access to viral DNA. Nat Immunol 7: 49-56, 2006.
9. Beg AA. Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses. Trends Immunol 23: 509-512, 2002.
10. Bekeredjian-Ding IB, Wagner M, Hornung V, Giese T, Schnurr M, Endres S, and Hartmann G. Plasmacytoid dendritic cells control TLR7 sensitivity of naive B cells via type I IFN. J Immunol 174: 4043-4050, 2005.
11. Beutler B and Rehli M. Evolution of the TIR, tolls and TLRs: functional inferences from computational biology. Curr Top Microbiol Immunol 270: 1-21, 2002.
12. Brentano F, Schorr O, Gay RE, Gay S, and Kyburz D. RNA released from necrotic synovial fluid cells activates rheumatoid arthritis synovial fibroblasts via Toll-like receptor 3. Arthritis Rheum 52: 2656-2665, 2005.
13. Chen LF and Greene WC. Shaping the nuclear action of NF-κB. Nat Rev Mol Cell Biol 5: 392-401, 2004.
14. Christensen SR, Kashgarian M, Alexopoulou L, Flavell RA, Akira S, and Shlomchik MJ. Toll-like receptor 9 controls anti-DNA autoantibody production in murine lupus. J Exp Med 202: 321-331, 2005.
15. Chuang TH and Ulevitch RJ. Cloning and characterization of a subfamily of human toll-like receptors: hTLR7, hTLR8 and hTLR9. Eur Cytokine Netw 11: 372-378, 2000.
16. Crozat K and Beutler B. TLR7: a new sensor of viral infection. Proc Natl Acad Sci USA 101: 6835-6836, 2004.
17. Diebold SS, Kaisho T, Hemmi H, Akira S, and Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 303: 1529-1531, 2004.
18. Dong L, Ito S, Ishii KJ, and Klinman DM. Suppressive oligodeoxynucleotides delay the onset of glomerulonephritis and prolong survival in lupus-prone NZB x NZW mice. Arthritis Rheum 52: 651-658, 2005.
19. Du X, Poltorak A, Wei Y, and Beutler B. Three novel mammalian toll-like receptors: gene structure, expression, and evolution. Eur Cytokine Netw 11: 362-371, 2000.
20. Edelmann KH, Richardson-Burns S, Alexopoulou L, Tyler KL, Flavell RA, and Oldstone MB. Does Toll-like receptor 3 play a biological role in virus infections? Virology 322: 231-238, 2004.
21. + DC correlates with unresponsiveness to imidazoquinolines. Eur J Immunol 33: 827-833, 2003.
22. Goldstein DR, Tesar BM, Akira S, and Lakkis FG. Critical role of the Toll-like receptor signal adaptor protein MyD88 in acute allograft rejection. J Clin Invest 111: 1571-1578, 2003.
23. Han KJ, Su X, Xu LG, Bin LH, Zhang J, and Shu HB. Mechanisms of the TRIF-induced interferon-stimulated response element and NF-κB activation and apoptosis pathways. J Biol Chem 279: 15652-15661, 2004.
24. Heeg K and Zimmermann S. CpG DNA as a Th1 trigger. Int Arch Allergy Immunol 121: 87-97, 2000.
25. Heikenwalder M, Polymenidou M, Junt T, Sigurdson C, Wagner H, Akira S, Zinkernagel R, and Aguzzi A. Lymphoid follicle destruction and immunosuppression after repeated CpG oligodeoxynucleotide administration. Nat Med 10: 187-192, 2004.
26. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, and Bauer S. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303: 1526-1529, 2004.
27. Heinz S, Haehnel V, Karaghiosoff M, Schwarzfischer L, Muller M, Krause SW, and Rehli M. Species-specific regulation of Toll-like receptor 3 genes in men and mice. J Biol Chem 278: 21502-21509, 2003.
28. Heit A, Huster KM, Schmitz F, Schiemann M, Busch DH, and Wagner H. CpG-DNA aided cross-priming by cross-presenting B cells. J Immunol 172: 1501-1507, 2004.
29. Hemmi H, Kaisho T, Takeuchi O, Sato S, Sanjo H, Hoshino K, Horiuchi T, Tomizawa H, Takeda K, and Akira S. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol 3: 196-200, 2002.
30. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, Matsumoto M, Hoshino K, Wagner H, Takeda K, and Akira S. A Toll-like receptor recognizes bacterial DNA. Nature 408: 740-745, 2000.
31. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T, Endres S, and Hartmann G. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 168: 4531-4537, 2002.
32. Ichikawa HT, Williams LP, and Segal BM. Activation of APCs through CD40 or Toll-like receptor 9 overcomes tolerance and precipitates autoimmune disease. J Immunol 169: 2781-2787, 2002.
33. Johnson RJ, Gretch DR, Yamabe H, Hart J, Bacchi CE, Hartwell P, Couser WG, Corey L, Wener MH, Alpers CE, and Willson R. Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med 328: 465-470, 1993.
34. Kapsenberg ML. Dendritic-cell control of pathogen-driven T-cell polarization. Nat Rev Immunol 3: 984-993, 2003.
35. Kariko K, Bhuyan P, Capodici J, and Weissman D. Small interfering RNAs mediate sequence-independent gene suppression and induce immune activation by signalling through toll-like receptor 3. J Immunol 172: 6545-6549, 2004.
36. Kariko K, Ni H, Capodici J, Lamphier M, and Weissman D. mRNA is an endogenous ligand for Toll-like receptor 3. J Biol Chem 279: 12542-12550, 2004.
37. Ketteler M, Kunter U, and Floege J. An update on herpes virus infections in graft recipients. Nephrol Dial Transplant 18: 1703-1706, 2003.
38. Krieg AM. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 20: 709-760, 2002.
39. Krieg AM, Yi AK, Matson S, Waldschmidt TJ, Bishop GA, Teasdale R, Koretzky GA, and Klinman DM. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374: 546-549, 1995.
40. Latz E, Schoenemeyer A, Visintin A, Fitzgerald KA, Monks BG, Knetter CF, Lien E, Nilsen NJ, Espevik T, and Golenbock DT. TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 5: 190-198, 2004.
41. Leadbetter EA, Rifkin IR, Hohlbaum AM, Beaudette BC, Shlomchik MJ, and Marshak-Rothstein A. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 416: 603-607, 2002.
42. Lemaitre B. The road to Toll. Nat Rev Immunol 4: 521-527, 2004.
43. Lemaitre B, Nicolas E, Michaut L, Reichhart JM, and Hoffmann JA. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86: 973-983, 1996.
44. Lenert P. Inhibitory oligodeoxynucleotides - therapeutic promise for systemic autoimmune diseases? Clin Exp Immunol 140: 1-10, 2005.
45. Lore K, Betts MR, Brenchley JM, Kuruppu J, Khojasteh S, Perfetto S, Roederer M, Seder RA, and Koup RA. Toll-like receptor ligands modulate dendritic cells to augment cytomegalovirus- and HIV-1-specific T cell responses. J Immunol 171: 4320-4328, 2003.
46. Lund JM, Alexopoulou L, Sato A, Karow M, Adams NC, Gale NW, Iwasaki A, and Flavell RA. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci USA 101: 5598-5603, 2004.
47. Marras D, Bruggeman LA, Gao F, Tanji N, Mansukhani MM, Cara A, Ross MD, Gusella GL, Benson G, D'Agati VD, Hahn BH, Klotman ME, and Klotman PE. Replication and compartmentalization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. Nat Med 8: 522-526, 2002.
48. Matsumoto M, Funami K, Oshiumi H, and Seya T. Toll-like receptor 3: a link between toll-like receptor, interferon and viruses. Microbiol Immunol 48: 147-154, 2004.
49. Matzinger P. The danger model: a renewed sense of self. Science 296: 301-305, 2002.
50. Meylan E, Burns K, Hofmann K, Blancheteau V, Martinon F, Kelliher M, and Tschopp J. RIP1 is an essential mediator of Toll-like receptor 3-induced NF-κB activation. Nat Immunol 5: 503-507, 2004.
51. Miyata M, Kobayashi H, Sasajima T, Sato Y, and Kasukawa R. Unmethylated oligo-DNA containing CpG motifs aggravates collagen-induced arthritis in mice. Arthritis Rheum 43: 2578-2582, 2000.
52. Nagase H, Okugawa S, Ota Y, Yamaguchi M, Tomizawa H, Matsushima K, Ohta K, Yamamoto K, and Hirai K. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc Natl Acad Sci USA 101: 5598-5603, 2004.
53. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, and Lanzavecchia A. Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 6: 769-776, 2005.
54. Patole P, Gröne HJ, Segerer S, Ciubar R, Belemezova E, Henger A, Kretzler M, Schlöndorff D, and Anders HJ. Viral double-stranded RNA aggravates lupus nephritis through Toll-like receptor-3 on glomerular mesangial cells and antigen-presenting cells. J Am Soc Nephrol 16: 1326-1338, 2005.
55. Patole P, Zecher D, Pawar RD, Gröne HJ, Schlöndorff D, and Anders HJ. G-rich DNA suppresses systemic lupus. J Am Soc Nephrol 16: 3273-3280, 2005.
56. Pawar RD, Patole PS, Zecher D, Kretzler M, Schlöndorff D, and Anders HJ. Toll-like receptor-7 modulates immune complex glomerulonephritis. J Am Soc Nephrol 17: 141-149, 2006.
57. Picard C, Puel A, Bonnet M, Ku CL, Bustamante J, Yang K, Soudais C, Dupuis S, Feinberg J, Fieschi C, Elbim C, Hitchcock R, Lammas D, Davies G, Al-Ghonaium A, Al-Rayes H, Al-Jumaah S, Al-Hajjar S, Al-Mohsen IZ, Frayha HH, Rucker R, Hawn TR, Aderem A, Tufenkeji H, Haraguchi S, Day NK, Good RA, Gougerot-Pocidalo MA, Ozinsky A, and Casanova JL. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 299: 2076-2079, 2003.
58. Popa ER, Stegeman CA, Kallenberg CG, and Tervaert JW. Staphylococcus aureus and Wegener's granulomatosis. Arthritis Res 4: 77-79, 2002.
59. Rifkin IR, Leadbetter EA, Busconi L, Viglianti G, and Marshak-Rothstein A. Toll-like receptors, endogenous ligands, and systemic autoimmune disease. Immunol Rev 204: 27-42, 2005.
60. Samstein B, Johnson GB, and Platt JL. Toll-like receptor-4 and allograft responses. Transplantation 77: 475-477, 2004.
61. Sauder DN, Smith MH, Senta-McMillian T, Soria I, and Meng TC. Randomized, single-blind, placebo-controlled study of topical application of the immune response modulator resiquimod in healthy adults. Antimicrob Agents Chemother 47: 3846-3852, 2003.
62. Schroder M and Bowie AG. TLR3 in antiviral immunity: key player or bystander? Trends Immunol 26: 462-468, 2005.
63. Seong SY and Matzinger P. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat Rev Immunol 4: 469-478, 2004.
64. Soderberg-Naucler C and Emery VC. Viral infections and their impact on chronic renal allograft dysfunction. Transplantation 71: SS24-SS30, 2001.
65. Spruance SL, Tyring SK, Smith MH, and Meng TC. Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: a pilot study. J Infect Dis 184: 196-200, 2001.
66. Stacey KJ, Young GR, Clark F, Sester DP, Roberts TL, Naik S, Sweet MJ, and Hume DA. The molecular basis for the lack of immunostimulatory activity of vertebrate DNA. J Immunol 170: 3614-3620, 2003.
67. Stegeman CA, Tervaert JW, de Jong PE, and Kallenberg CG. Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group. N Engl J Med 335: 16-20, 1996.
68. Storni T, Ruedl C, Schwarz K, Schwendener RA, Renner WA, and Bachmann MF. Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol 172: 1777-1785, 2004.
69. Tabeta K, Georgel P, Janssen E, Du X, Hoebe K, Crozat K, Mudd S, Shamel L, Sovath S, Goode J, Alexopoulou L, Flavell RA, and Beutler B. Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. Proc Natl Acad Sci USA 101: 3516-3521, 2004.
70. Tesar BM, Zhang J, Li Q, and Goldstein DR. TH1 immune responses to fully MHC mismatched allografts are diminished in the absence of MyD88, a Toll-like receptor signal adaptor protein. Am J Transplant 4: 1429-1439, 2004.
71. Tissari J, Siren J, Meri S, Julkunen I, and Matikainen S. IFN-α enhances TLR3-mediated antiviral cytokine expression in human endothelial and epithelial cells by up-regulating TLR3 expression. J Immunol 174: 4289-4294, 2005.
72. Tsoulfas G, Takahashi Y, Ganster RW, Yagnik G, Guo Z, Fung JJ, Murase N, and Geller DA. Activation of the lipopolysaccharide signaling pathway in hepatic transplantation preservation injury. Transplantation 74: 7-13, 2002.
73. Tsuboi N, Yoshikai Y, Matsuo S, Kikuchi T, Iwami K, Nagai Y, Takeuchi O, Akira S, and Matsuguchi T. Roles of toll-like receptors in C-C chemokine production by renal tubular epithelial cells. J Immunol 169: 2026-2033, 2002.
74. Ulevitch RJ. Therapeutics targeting the innate immune system. Nat Rev Immunol 4: 512-520, 2004.
75. Wagner H. The immunobiology of the TLR9 subfamily. Trends Immunol 25: 381-386, 2003.
76. Walker C and Zuany-Amorim C. New trends in immunotherapy to prevent atopic diseases. Trends Pharmacol Sci 22: 84-90, 2001.
77. Wang T, Town T, Alexopoulou L, Anderson JF, Fikrig E, and Flavell RA. Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis. Nat Med 10: 1366-1373, 2004.
78. Winston JA, Bruggeman LA, Ross MD, Jacobson J, Ross L, D'Agati VD, Klotman PE, and Klotman ME. Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection. N Engl J Med 344: 1979-1984, 2001.
79. Wolfs TG, Buurman WA, van Schadewijk A, de Vries B, Daemen MA, Hiemstra PS, and van't Veer C. In vivo expression of Toll-like receptor 2 and 4 by renal epithelial cells: IFN-γ and TNF-α mediated up-regulation during inflammation. J Immunol 168: 1286-1293, 2002.
80. Wörnle M, Schmidt H, Banas B, Merkle M, Henger A, Roeder M, Blattner S, Bock E, Kretzler M, Gröne HJ, and Schlöndorff D. Novel role of Toll-like receptor-3 in hepatitis-associated membranoproliferative glomerulonephritis. Am J Pathol 168: 370-385, 2006.
81. Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, Takeuchi O, Sugiyama M, Okabe M, Takeda K, and Akira S. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 301: 640-643, 2003.
82. Yamamoto M, Sato S, Mori K, Hoshino K, Takeuchi O, Takeda K, and Akira S. Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-β promoter in the Toll-like receptor signaling. J Immunol 169: 6668-6672, 2002.
83. Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, Taira K, Akira S, and Fujita T. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. Nat Immunol 5: 730-737, 2004.